- Home
- ATER vs BCTX Comparison
ATER vs BCTX Comparison
Compare ATER & BCTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ATER
- BCTX
- Stock Information
- Founded
- ATER 2014
- BCTX 2014
- Country
- ATER United States
- BCTX Canada
- Employees
- ATER N/A
- BCTX N/A
- Industry
- ATER Home Furnishings
- BCTX Biotechnology: Pharmaceutical Preparations
- Sector
- ATER Consumer Discretionary
- BCTX Health Care
- Exchange
- ATER Nasdaq
- BCTX Nasdaq
- Market Cap
- ATER 19.5M
- BCTX 15.8M
- IPO Year
- ATER N/A
- BCTX N/A
- Fundamental
- Price
- ATER $2.14
- BCTX $3.61
- Analyst Decision
- ATER Strong Buy
- BCTX Strong Buy
- Analyst Count
- ATER 1
- BCTX 1
- Target Price
- ATER N/A
- BCTX $32.00
- AVG Volume (30 Days)
- ATER 2.8M
- BCTX 42.8K
- Earning Date
- ATER 05-06-2025
- BCTX 03-12-2025
- Dividend Yield
- ATER N/A
- BCTX N/A
- EPS Growth
- ATER N/A
- BCTX N/A
- EPS
- ATER N/A
- BCTX N/A
- Revenue
- ATER $99,045,000.00
- BCTX N/A
- Revenue This Year
- ATER $5.62
- BCTX N/A
- Revenue Next Year
- ATER $8.63
- BCTX N/A
- P/E Ratio
- ATER N/A
- BCTX N/A
- Revenue Growth
- ATER N/A
- BCTX N/A
- 52 Week Low
- ATER $1.86
- BCTX $0.35
- 52 Week High
- ATER $3.95
- BCTX $7.87
- Technical
- Relative Strength Index (RSI)
- ATER 47.50
- BCTX 46.14
- Support Level
- ATER $2.09
- BCTX $3.44
- Resistance Level
- ATER $2.56
- BCTX $4.36
- Average True Range (ATR)
- ATER 0.29
- BCTX 0.38
- MACD
- ATER -0.02
- BCTX -0.09
- Stochastic Oscillator
- ATER 5.56
- BCTX 12.69
About ATER Aterian Inc.
Aterian Inc is a technology-enabled consumer products company. Its product categories include home and kitchen appliances, kitchenware, environmental appliances (dehumidifiers and air conditioners), beauty-related products and, consumer electronics. It has various owned and operated brands including Vremi, Healing Solutions, Xtava, TRUWEO, Spiralize, Pohl+Schmitt, and RIF6. The company generates revenue through the online sales of various consumer products that are sold online.
About BCTX BriaCell Therapeutics Corp.
BriaCell Therapeutics Corp is a clinical-stage immuno-oncology company. The group is developing an entirely new class of targeted immunotherapies to transform cancer care. Its product candidate Bria-IMT, is being evaluated in a pivotal Phase 3 combination study for metastatic breast cancer (MBC is breast cancer that has spread to other tissues). Bria-IMT is a targeted cell-based immunotherapy. The company is engaged in developing a Bria-OTS platform of personalized off-the-shelf cell-based immunotherapies. It is being evaluated in a Phase 1/2 clinical study and the treatment is initially focused on patients with breast cancer with an extension to prostate cancer, and other cancers.